CN101564374A - Medicinal in situ forming eye gel - Google Patents
Medicinal in situ forming eye gel Download PDFInfo
- Publication number
- CN101564374A CN101564374A CNA200810105214XA CN200810105214A CN101564374A CN 101564374 A CN101564374 A CN 101564374A CN A200810105214X A CNA200810105214X A CN A200810105214XA CN 200810105214 A CN200810105214 A CN 200810105214A CN 101564374 A CN101564374 A CN 101564374A
- Authority
- CN
- China
- Prior art keywords
- eye
- gel
- add
- sodium
- hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011065 in-situ storage Methods 0.000 title abstract description 7
- 229920002148 Gellan gum Polymers 0.000 claims abstract description 69
- 239000000216 gellan gum Substances 0.000 claims abstract description 69
- 235000010492 gellan gum Nutrition 0.000 claims abstract description 68
- 239000003814 drug Substances 0.000 claims abstract description 43
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 239000000463 material Substances 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 74
- 239000008215 water for injection Substances 0.000 claims description 28
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 26
- 239000004327 boric acid Substances 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 26
- 238000002347 injection Methods 0.000 claims description 26
- 229910021538 borax Inorganic materials 0.000 claims description 25
- 239000004328 sodium tetraborate Substances 0.000 claims description 25
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 23
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 21
- NRBJWZSFNGZBFQ-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 NRBJWZSFNGZBFQ-UHFFFAOYSA-N 0.000 claims description 21
- 229960004055 ciprofloxacin lactate Drugs 0.000 claims description 21
- 229960003923 gatifloxacin Drugs 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 229960000707 tobramycin Drugs 0.000 claims description 14
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 14
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000011734 sodium Substances 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 8
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 229960004150 aciclovir Drugs 0.000 claims description 6
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229960000265 cromoglicic acid Drugs 0.000 claims description 6
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 5
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 5
- 229960005323 phenoxyethanol Drugs 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 4
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 4
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 claims description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 4
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims description 4
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims description 4
- WTQYWNWRJNXDEG-RBZJEDDUSA-N [(1r,3s,5r,6s)-6-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] (2s)-3-hydroxy-2-phenylpropanoate Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@@H]3[C@@H](O)C[C@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-RBZJEDDUSA-N 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- 229960004099 azithromycin Drugs 0.000 claims description 4
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 4
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 4
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 4
- 229960004926 chlorobutanol Drugs 0.000 claims description 4
- 229940097572 chloromycetin Drugs 0.000 claims description 4
- 229960002925 clonidine hydrochloride Drugs 0.000 claims description 4
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims description 4
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 4
- 229960003630 ketotifen fumarate Drugs 0.000 claims description 4
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 229960001180 norfloxacin Drugs 0.000 claims description 4
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 4
- 108010019657 polymyxin drug combination nystatin neomycin dimethicone acetarsol Proteins 0.000 claims description 4
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 229960000329 ribavirin Drugs 0.000 claims description 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229960003080 taurine Drugs 0.000 claims description 4
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 4
- 229960004791 tropicamide Drugs 0.000 claims description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 4
- 229960001763 zinc sulfate Drugs 0.000 claims description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 4
- 229960003405 ciprofloxacin Drugs 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- CIKNYWFPGZCHDL-ZHFUJENKSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N CIKNYWFPGZCHDL-ZHFUJENKSA-N 0.000 claims description 2
- UHHHTIKWXBRCLT-VDBOFHIQSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;ethanol;hydrate;dihydrochloride Chemical compound O.Cl.Cl.CCO.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O UHHHTIKWXBRCLT-VDBOFHIQSA-N 0.000 claims description 2
- YCIHPQHVWDULOY-FMZCEJRJSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O YCIHPQHVWDULOY-FMZCEJRJSA-N 0.000 claims description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
- IWEGDQUCWQFKHS-UHFFFAOYSA-N 1-(1,3-dioxolan-2-ylmethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(CC2OCCO2)N=C1 IWEGDQUCWQFKHS-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 claims description 2
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 claims description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 2
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 claims description 2
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 claims description 2
- RHLJLALHBZGAFM-UHFFFAOYSA-N Bunazosinum Chemical compound C1CN(C(=O)CCC)CCCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 RHLJLALHBZGAFM-UHFFFAOYSA-N 0.000 claims description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 claims description 2
- PVMYGBPTLGTGRN-UHFFFAOYSA-N N.[I] Chemical compound N.[I] PVMYGBPTLGTGRN-UHFFFAOYSA-N 0.000 claims description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 claims description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 2
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 claims description 2
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims description 2
- 108010058907 Tiopronin Proteins 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 2
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 claims description 2
- OPXFZJLGAZHBMA-UHFFFAOYSA-N [[1-(carbamothioylhydrazinylidene)-3-(1,3-dioxoisoindol-2-yl)butan-2-ylidene]amino]thiourea Chemical compound C1=CC=C2C(=O)N(C(C)C(C=NNC(N)=S)=NNC(N)=S)C(=O)C2=C1 OPXFZJLGAZHBMA-UHFFFAOYSA-N 0.000 claims description 2
- 229960000583 acetic acid Drugs 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- 229960004821 amikacin Drugs 0.000 claims description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 claims description 2
- 229960003731 amlexanox Drugs 0.000 claims description 2
- LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 claims description 2
- 229950010351 amosulalol Drugs 0.000 claims description 2
- 229960002028 atropine sulfate Drugs 0.000 claims description 2
- 229960005149 bendazac Drugs 0.000 claims description 2
- BYFMCKSPFYVMOU-UHFFFAOYSA-N bendazac Chemical compound C12=CC=CC=C2C(OCC(=O)O)=NN1CC1=CC=CC=C1 BYFMCKSPFYVMOU-UHFFFAOYSA-N 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960005354 betamethasone sodium phosphate Drugs 0.000 claims description 2
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 claims description 2
- 229960004347 betaxolol hydrochloride Drugs 0.000 claims description 2
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002470 bimatoprost Drugs 0.000 claims description 2
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 2
- 229960003679 brimonidine Drugs 0.000 claims description 2
- 229960001724 brimonidine tartrate Drugs 0.000 claims description 2
- 229960002467 bunazosin Drugs 0.000 claims description 2
- 229950004443 bunolol Drugs 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229960002165 carteolol hydrochloride Drugs 0.000 claims description 2
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 claims description 2
- CZPLANDPABRVHX-UHFFFAOYSA-N cascade blue Chemical compound C=1C2=CC=CC=C2C(NCC)=CC=1C(C=1C=CC(=CC=1)N(CC)CC)=C1C=CC(=[N+](CC)CC)C=C1 CZPLANDPABRVHX-UHFFFAOYSA-N 0.000 claims description 2
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 claims description 2
- 229940074393 chlorogenic acid Drugs 0.000 claims description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 2
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 2
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 229960001193 diclofenac sodium Drugs 0.000 claims description 2
- SZGZILRQIYNODJ-UHFFFAOYSA-L disodium;7,12-dihydroquinoxalino[3,2-b]phenazine-2,9-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC=C2N=C(C=C3C(NC4=CC=C(C=C4N3)S(=O)(=O)[O-])=C3)C3=NC2=C1 SZGZILRQIYNODJ-UHFFFAOYSA-L 0.000 claims description 2
- 229960001172 doxycycline hyclate Drugs 0.000 claims description 2
- 229960003913 econazole Drugs 0.000 claims description 2
- CHNUOJQWGUIOLD-NFZZJPOKSA-N epalrestat Chemical compound C=1C=CC=CC=1\C=C(/C)\C=C1/SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-NFZZJPOKSA-N 0.000 claims description 2
- 229950010170 epalrestat Drugs 0.000 claims description 2
- CHNUOJQWGUIOLD-UHFFFAOYSA-N epalrestate Natural products C=1C=CC=CC=1C=C(C)C=C1SC(=S)N(CC(O)=O)C1=O CHNUOJQWGUIOLD-UHFFFAOYSA-N 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims description 2
- 229960001048 fluorometholone Drugs 0.000 claims description 2
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 claims description 2
- 229960003898 flurbiprofen sodium Drugs 0.000 claims description 2
- 229960002963 ganciclovir Drugs 0.000 claims description 2
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000012362 glacial acetic acid Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 2
- 235000003969 glutathione Nutrition 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 239000008503 houttuyninum Substances 0.000 claims description 2
- CAOOISJXWZMLBN-PPHPATTJSA-N htn0d03vrz Chemical compound Cl.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 CAOOISJXWZMLBN-PPHPATTJSA-N 0.000 claims description 2
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 2
- -1 hydroxypropyl Chemical group 0.000 claims description 2
- 229960000905 indomethacin Drugs 0.000 claims description 2
- UDIIBEDMEYAVNG-ZKFPOVNWSA-N isepamicin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)O)[C@@H](N)C[C@H]1NC(=O)[C@@H](O)CN UDIIBEDMEYAVNG-ZKFPOVNWSA-N 0.000 claims description 2
- 229960000798 isepamicin Drugs 0.000 claims description 2
- 229960004130 itraconazole Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 229960004384 ketorolac tromethamine Drugs 0.000 claims description 2
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001160 latanoprost Drugs 0.000 claims description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 2
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229960001595 lincomycin hydrochloride Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229960002704 metipranolol Drugs 0.000 claims description 2
- BQIPXWYNLPYNHW-UHFFFAOYSA-N metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 claims description 2
- 229960002509 miconazole Drugs 0.000 claims description 2
- 229960003106 micronomicin sulfate Drugs 0.000 claims description 2
- MQDGQSCLOYLSEK-SCFBDNQUSA-N micronomicin sulfate Chemical compound OS(O)(=O)=O.O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N MQDGQSCLOYLSEK-SCFBDNQUSA-N 0.000 claims description 2
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 claims description 2
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 claims description 2
- 229960005016 naphazoline Drugs 0.000 claims description 2
- 229960003255 natamycin Drugs 0.000 claims description 2
- 239000004311 natamycin Substances 0.000 claims description 2
- 235000010298 natamycin Nutrition 0.000 claims description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 2
- 229960004832 netilmicin sulfate Drugs 0.000 claims description 2
- 229960001699 ofloxacin Drugs 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 claims description 2
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
- 229960002516 physostigmine salicylate Drugs 0.000 claims description 2
- HZOTZTANVBDFOF-PBCQUBLHSA-N physostigmine salicylate Chemical compound OC(=O)C1=CC=CC=C1O.C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C HZOTZTANVBDFOF-PBCQUBLHSA-N 0.000 claims description 2
- 229960001963 pilocarpine nitrate Drugs 0.000 claims description 2
- 229960000293 pirenzepine hydrochloride Drugs 0.000 claims description 2
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- 229920001992 poloxamer 407 Polymers 0.000 claims description 2
- 229940044476 poloxamer 407 Drugs 0.000 claims description 2
- 229960002800 prednisolone acetate Drugs 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229940108325 retinyl palmitate Drugs 0.000 claims description 2
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 2
- 239000011769 retinyl palmitate Substances 0.000 claims description 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- HPPWMWCITPGPKK-UHFFFAOYSA-M sodium;1-hydroxy-3-oxododecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCC(=O)CC(O)S([O-])(=O)=O HPPWMWCITPGPKK-UHFFFAOYSA-M 0.000 claims description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 2
- GNMBMOULKUXEQF-UHFFFAOYSA-M sodium;2-(3-fluoro-4-phenylphenyl)propanoate;dihydrate Chemical compound O.O.[Na+].FC1=CC(C(C([O-])=O)C)=CC=C1C1=CC=CC=C1 GNMBMOULKUXEQF-UHFFFAOYSA-M 0.000 claims description 2
- 229960002673 sulfacetamide Drugs 0.000 claims description 2
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 claims description 2
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004306 sulfadiazine Drugs 0.000 claims description 2
- 229960002494 tetracaine hydrochloride Drugs 0.000 claims description 2
- 229960004605 timolol Drugs 0.000 claims description 2
- 229960004402 tiopronin Drugs 0.000 claims description 2
- 229950008187 tosufloxacin Drugs 0.000 claims description 2
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 claims description 2
- 229960005342 tranilast Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 claims description 2
- 229960003962 trifluridine Drugs 0.000 claims description 2
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims description 2
- 229930004006 tropane Natural products 0.000 claims description 2
- 229960003232 troxerutin Drugs 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 229960004740 voriconazole Drugs 0.000 claims description 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 claims description 2
- 229960000306 zinc gluconate Drugs 0.000 claims description 2
- 239000011670 zinc gluconate Substances 0.000 claims description 2
- 235000011478 zinc gluconate Nutrition 0.000 claims description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 1
- 210000001508 eye Anatomy 0.000 abstract description 69
- 230000000694 effects Effects 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 74
- 239000012528 membrane Substances 0.000 description 27
- 239000003889 eye drop Substances 0.000 description 26
- 238000012360 testing method Methods 0.000 description 23
- 229960000848 foscarnet sodium Drugs 0.000 description 21
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 21
- 239000007788 liquid Substances 0.000 description 15
- 238000009835 boiling Methods 0.000 description 14
- 210000004087 cornea Anatomy 0.000 description 14
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 14
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 14
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 14
- 150000001768 cations Chemical class 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000008363 phosphate buffer Substances 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 206010014568 Empyema Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 229940012356 eye drops Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 206010023332 keratitis Diseases 0.000 description 5
- NZKFUBQRAWPZJP-BXKLGIMVSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NZKFUBQRAWPZJP-BXKLGIMVSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003885 eye ointment Substances 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000006069 Corneal Opacity Diseases 0.000 description 2
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960003290 cortisone acetate Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- ROFNJLCLYMMXCT-UHFFFAOYSA-N 4-aminohexanoic acid Chemical compound CCC(N)CCC(O)=O ROFNJLCLYMMXCT-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004083 nasolacrimal duct Anatomy 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicinal in situ forming eye gel preparation, and belongs to the field of pharmacy. Active ingredients of the preparation come from bulk medicaments of the medicament, gel base materials of the preparation mainly comprise Gellan gum which is 0.4 to 0.7 percent of the weight of a finished product. The technical proposal overcomes the defects of low bioavailability, inconvenient use, short detention time and the like of the prior eye preparation, and achieves the effects of reducing applied dosage, prolonging the detention time in the eyes, convenient use, accurate applied dosage and the like.
Description
Technical field
The present invention relates to a kind of medicinal in situ forming eye gel preparation, especially a kind of is the situ forming eye gel preparation of main gel base material with gellan gum, belongs to field of medicaments.
Background technology
In present ophthalmic preparation, eye drop as a kind of traditional dosage form have easy to use, compliance good, advantage such as cheap, but its medicine shortcoming that the holdup time is short within the eye, bioavailability is low makes its curative effect be subjected to very big influence.Studies show that: the volume of one after another drop of eye liquid is substantially between 25～50ul, if do not bat an eyelid, the ophthalmic medicine liquid volume is only at 30ul, if nictation then be reduced to 10ul, so the medicine major part of eye external is not to enter ocular tissue, but lose through nasolacrimal duct system and eyelid slit flow.According to tear kinetics, ophthalmic solution is very short in the holdup time on eye surface, absorbed medication amount only is the sub-fraction of dosage usually, even medicine at eyeball surface, because the dilution of nictation and tear, concentration medicine reduces, medicine ask minimizing as the time spent, so solution must repeat administration, could guarantee effective drug level, increase the action time of medicine, reach higher drug absorption degree, this just needs frequent dripping eyedrop, but frequent drug administration very easily causes the lasting damage of ocular tissue, use inconvenience, the patient also is difficult to adhere to.
Except that eye drop, the ophthalmic preparation on the market mainly also has Eye ointments, common gel for eye etc.Though Eye ointments can keep certain drug level for a long time, but general only application just before going to bed at night, because the patient is coated with the back influence of applying ointment and looks thing, do not see thing, and use at night, be coated with the back sleep of applying ointment, do not need eyes to look thing, this also is the shortcoming of Eye ointments, uses daytime extremely inconvenient; Common gel for eye can the long period be trapped in mucous membrane surface, improve the thing availability that looks unfamiliar, but the viscosity of this type of preparation is big, have shortcomings such as production technology operating difficulties, clinical using dosage are inaccurate.
Along with the continuous development of newtype drug adjuvant, a kind of new situ forming eye gel preparation begins to receive publicity.Instant gel is a kind of macromolecular solution agent, its formation mechanism is to utilize macromolecular material to stimulate the response of (physiological environment that the inside and outside is different such as pH, temperature, ion etc.) to external world, make high molecular polymer issue the reversible change of diffusing state estranged or conformation, finish by the conversion process of solution to gel at physiological condition.This type of dosage form has certain novelty: be in a liquid state in storage period, be semi-solid state after splashing into ophthalmic, not only can solve the problem that the common eye drops ophthalmic holdup time is short, bioavailability is not high, also overcome common gel for eye use high viscosity and lacked good spreadability, the uppity problem of dosage, its unique solution-gel conversion character make it have advantages such as preparation is simple, easy to use, strong with agents area especially mucosal tissue affinity, the holdup time is long concurrently.
Gellan gum (gellan gum) is a kind of Microbial exopolysaccharides, is the water-soluble polymer that generates by fermentation, is produced by U.S. Kelco company at first.Gellan gum has double-spiral structure, and its distinguishing feature is to form gel with monovalence or bivalent cation effect.In a single day gellan gum contacts the cation (Na+ of physiological concentration, K+, Ca2+), glucuronic acid in the structure is neutralized, cation mediated cohesion promptly takes place, produce solution-gel phase transformation, its gel ability is subjected to the influence of cation type, cation concn and himself concentration, bivalent cation promotes that than monovalent cation the ability of gellan gum gel is strong, and wherein Ca2+ is more effective than Mg2+; Bivalent cation makes gellan gum form the heat irreversible gel, and monovalent cation makes gellan gum form the thermal reversibility gel.When cation existed, the intensity of the gel that some gellan gum forms in pH4.0～8.0 changed with pH hardly.
How gellan gum being applied to ophthalmic preparation, is the emphasis of present ophthalmic remedy research.Therefore, solving the ins and outs of gellan gum in the preparation medicinal in situ forming eye gel, make it really become product, is the problem that at first will solve.
Summary of the invention
The purpose of this invention is to provide a kind of medicinal in situ forming eye gel preparation, particularly is the instant gel for eye of main gel base material with gellan gum, so that improve the result of use of product, convenient clinical use better meets needs of medical treatment.The base material of gel described in the present invention is meant the precursor substance of gel, when mixing with the water equal solvent and reaching certain gelling condition, just can become gel.
In conjunction with existing result of study, the present invention seeks to be achieved through the following technical solutions:
We combine medicine with instant gel base material gellan gum, the conventional adjuvant that is aided with ophthalmic preparation has again been made instant gel for eye.Used effective ingredient is selected from but is not limited to Gatifloxacin; pirenzepine hydrochloride; raceanisodamine; pilocarpine nitrate; isoproterenol; bunazosin; maleic acid Saimaa Luo Er; the husky tropane in a left side; latanoprost; Quwo prostatitis element; bimatoprost; timolol; brimonidine tartrate; betaxolol hydrochloride; carteolol hydrochloride; erythromycin; chloromycetin; ciprofloxacin; ciprofloxacin lactate; ofloxacin; levofloxacin; moxifloxacin hydrochloride; levofloxacin hydrochloride; macrodex; neo-houttuyninum; atropine sulfate; ribavirin; ftibamzone; tiopronin; ciclosporin; ganciclovir; vitamin A palmitate; azithromycin; clarithromycin; raceanisodamine; ketotifen fumarate; netilmicin sulfate; indomethacin; phacolin; Bernetine Sodium; glutathion; vitamin B12; vitamin B6; taurine; bendazac lysine; tranilast; metipranolol; doxycycline hyclate; troxerutin; dexamethasone sodium phosphate; polygynax; fluorometholone; allantoin; chondroitin sulfate; tropicamide; brimonidine; sodium cromoglicate; clonidine hydrochloride; tetracaine hydrochloride; prednisolone acetate; flurbiprofen sodium; ketotifen fumarate; norfloxacin; epalrestat; amosulalol; voriconazole; itraconazole; ammonia iodine peptide; isepamicin; pranoprofen; Bu Linzuo amine; sulphacetamide; chlortetracycline hydrochloride; trifluorothymidine; sodium chromoglicate; the left-handed bunolol of hydrochloric acid; mensiso; the toluenesulfonic acid tosufloxacin; betamethasone sodium phosphate; amlexanox; physostigmine salicylate; sulfadiazine; quadracycline; Naphazoline Chloridum; chlorphenamine maleate; tobramycin; gentamycin sulfate; lincomycin hydrochloride; oxymetazoline hydrochloride; ketorolac tromethamine; natamycin; Micronomicin Sulfate; Ciclosporin A; asparagic acid azithromycin; methylbromtropin; amikacin; fluconazol; ketoconazole; miconazole; econazole; diclofenac sodium; acyclovir; puerarin; zinc sulfate; zinc gluconate; Sodium Houttuyfonate; puerarin; chlorogenic acid; berberine hydrochloride; Borneolum Syntheticum; at least a in the Mentholum.
Specifically:
Gel is to be prepared into by medicine and suitable adjuvant, and in 100 parts of finished weights, used medicine is 0.01～2.5 part.Wherein, medicine soluble in water directly joins to dissolve in the water for injection and gets final product, and the little medicine of dissolubility then needs to dissolve with small amount of ethanol or other solvents earlier in water, slowly is added to the water again, fully stirs and makes dissolving.
In the preparation process of gel for eye, in order to guarantee the molding of preparation, except the conventional adjuvant of ophthalmic preparation, critical work is to select the gel base material that suits, adopts a kind of novel base material-gellan gum of transformation mutually among the present invention.Gellan gum is the ion-sensitive type adjuvant, and the preparation that makes for liquid, splashes into the cation (Na that runs into physiological concentration in the eye external
+, K
+, Ca
2+) gelling then takes place.The inventor is by great deal of experimental, and the result is that the amount of gel base material gellan gum is 0.4～0.7 part in 100 parts of finished weights; Further preferred, the consumption of gellan gum is 0.6 part.
In the preparation process of instant gel for eye, the inventor has tested again with in gellan gum and other base materials such as carbomer, hydroxypropyl emthylcellulose, poloxamer 407, poloxamer 188, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, methylcellulose, sodium alginate, the polyacrylic acid one or more and has carried out applied in any combination.So anyly carry out the behavior that applied in any combination prepares instant gel for eye with gellan gum and above-mentioned adjuvant and also all belong to protection scope of the present invention.
For molding and the steady quality that guarantees gel, also need to add the conventional adjuvant of a certain amount of ophthalmic preparation, i.e. pH regulator agent, isoosmotic adjusting agent, antibacterial and water.The used isoosmotic adjusting agent of inventor comprises at least a in glucose, boric acid, Borax, glycerol, propylene glycol, the mannitol, the pH regulator agent comprises at least a in hydrochloric acid, lactic acid, citric acid, glacial acetic acid, triethanolamine, boric acid, the Borax, and antibacterial comprises at least a in benzyl alcohol, chlorobutanol, benzalkonium chloride, benzalkonium bromide, phenoxyethanol, Metagin, second, the propyl ester.Through further test, the mixture of the inventor is preferred boric acid, Borax both can be brought into play the effect of pH regulator agent again as isoosmotic adjusting agent, can reduce the consumption of other adjuvants.
Instant gel for eye among the present invention need add isoosmotic adjusting agent and pH regulator agent, its addition and ratio with the pH value of regulating preparation reach 5～8, osmotic pressure reaches etc. ooze or near etc. ooze and be as the criterion; Add antibacterial, addition is enough to reach antibacterial purpose and is as the criterion.
The inventor finds in experimental study, and when the preparation medicinal in situ forming eye gel, the hyaluronate sodium that can also add the HYDROXYPROPYL BETA-CYCLODEXTRIN of 0～1 part polyoxyethylene sorbitan monoleate or 0～1 part or 0～1 part in 100 parts of finished products improves the state of preparation.After adding polyoxyethylene sorbitan monoleate or hyaluronate sodium, the supplementary product consumption of preparation reduces, and viscosity also reduces, the perfect preparation technology of preparation, after adding HYDROXYPROPYL BETA-CYCLODEXTRIN, the dissolubility of many slightly solubility compositions of part medicine improves, thereby has improved the bioavailability of preparation.
The inventor investigates through overtesting, determined following technology during the preparation of instant gel for eye: will add the gel base material in the water for injection, mixing adds isoosmotic adjusting agent, pH regulator agent, antibacterial etc., mixing again, adding is with the appropriate solvent dissolved drug, filter, add the injection water, filter to total amount, aseptic subpackaged, promptly.
Beneficial effect
Owing to contain Na in the tear
+, K
+And Ca
2+Etc. cation, gellan gum can form gel with these ionizations, eliminates from the cornea forefoot area thereby suppress medicine.Gellan gum has characteristics such as gel formation ability is strong, transparency is high, the acidproof heat-proof performance is good, is the gel base material of main component with it, is liquid in the preparation, good fluidity, bring convenience to preparation, become gel state, also possessed all advantages of gel and splash into ophthalmic.Thereby solved the defective of present ophthalmic preparation.
For effect of the present invention is described, embody the eye retentivity of instant gel for eye, the inventor has carried out following test:
Experiment one: Gatifloxacin instant gel for eye release in vitro degree is investigated
Test objective: investigate the release behaviour in vitro of Gatifloxacin instant gel for eye, and compare with eye drop.
Test material: Gatifloxacin instant gel for eye: get water for injection 800ml, add gellan gum 6g, stir, put in the boiling water bath, stir to clarify, add boric acid 12g, Borax 0.6g, ethyl hydroxybenzoate 0.8g, stir to clarify, be heated to 60 ℃, cross microporous filter membrane (0.8 μ m), stir and add Gatifloxacin 3g down, stir evenly, add the injection water, cross microporous filter membrane (0.22 μ m) to 1000ml, aseptic subpackaged, promptly.
Gatifloxacin eye drop (Kunming Laoboyuntang Pharmaceutical Co., Ltd. produces, and the dose contained with the Gatifloxacin instant gel for eye is identical)
Tianjin, island LC-2010A high performance liquid chromatograph
Tianjin, island CLASS-VP work station
Isotonic phosphate buffer liquid (contains NaH in the 1000ml solution
2PO
41.60g, Na
2HPO
47.58g NaCl 4.32g transfers pH to 7.40)
Test method: take by weighing each 3g of Gatifloxacin instant gel for eye and gatifloxacin eye drop, place bag filter respectively, (removing bubble in the bag) tightened with nylon wire in bag two, is fixed in the 250ml beaker, and release medium is isotonic phosphate buffer liquid 100ml, the bag upper edge is apart from liquid level 1cm, beaker places on the magnetic stirrer, and stirrer is about 2.5cm, temperature control (34 ± 1) ℃, the 5ml that takes a sample at regular intervals adds simultaneously with the fresh phosphate buffer of volume.
Measure the content (is testing index with the Gatifloxacin) of each sample of being got respectively with the HPLC method, represent with peak area.Calculate the diffusion release amount that adds up as follows:
C
i＝f(A
i)，Qn＝100Cn+5∑C
i(Q1＝100C
1 i，n＝1，2，3...)
(C
iBe drug level, A is for recording peak area, and Q is the drug accumulation burst size, and i, n are respectively the sampling number of times.)
Result of the test: Gatifloxacin instant gel for eye and gatifloxacin eye drop release in vitro curve are seen accompanying drawing 1.
Above-mentioned cumulative release curve is discharged equation model, and it has the one-level release rule as a result, and regression equation has good dependency.One-level release fit equation is: Log (Y
∝-Y)=-Kr * t/2.303+M.The release equation of Gatifloxacin gel for eye use of the present invention is: Log (Y
∝-Y)=-0.1814t+1.8524, correlation coefficient is 0.9968.
The result shows that the external drug release rate of gatifloxacin eye drop is very fast, and the 1h release reaches about 80%, enters plateau afterwards; And the Gatifloxacin instant gel for eye reaches about 80% in the 3h release, and drug release rate is mild, has slow release characteristic preferably.
Conclusion (of pressure testing): the Gatifloxacin instant gel for eye has slow release characteristic preferably.Improve medicine by the present invention and have feasibility in the bioavailability of eye.
Experiment two: foscarnet sodium instant gel for eye release in vitro degree is investigated
Test objective: investigate the release behaviour in vitro of foscarnet sodium instant gel for eye, and compare with eye drop.
Test material: foscarnet sodium instant gel for eye: get among gellan gum 5g and boric acid, the Borax adding water for injection 950ml, heated and boiled, be cooled to 80 ℃, add foscarnet sodium 5g, be cooled to 60 ℃ while stirring, add ethyl hydroxybenzoate 0.4g again, and add the injection water to 1000ml, and stirred 30 minutes, cross microporous filter membrane (0.22 μ m), aseptic subpackaged, promptly.
Foscarnet sodium eye drop (favorable to the people pharmaceutical factory of Jinting Pharmaceutical Co., Ltd. produces, and the dose contained with the foscarnet sodium instant gel for eye is identical)
Tianjin, island UV1100 spectrophotometer
Isotonic phosphate buffer liquid (contains NaH in the 1000ml solution
2PO
41.60g, Na
2HPO
47.58g NaCl 4.32g transfers pH to 7.40)
Test method: take by weighing foscarnet sodium instant gel for eye and each 3g of foscarnet sodium eye drop, place bag filter respectively, (removing bubble in the bag) tightened with nylon wire in bag two, is fixed in the 250ml beaker, and release medium is isotonic phosphate buffer liquid 100ml, the bag upper edge is apart from liquid level 1cm, beaker places on the magnetic stirrer, and stirrer is about 2.5cm, temperature control (34 ± 1) ℃, the 5ml that takes a sample at regular intervals adds simultaneously with the fresh phosphate buffer of volume.
Measure the content of the foscarnet sodium in each sample of being got respectively with the HPLC method.Calculate the diffusion release amount that adds up as follows:
C
i＝f(A
i)，Qn＝100Cn+5∑C
i(Q1＝100C
1?i，n＝1，2，3...)
(C
iBe drug level, A is for recording peak area, and Q is the drug accumulation burst size, and i, n are respectively the sampling number of times.)
Result of the test: foscarnet sodium instant gel for eye and foscarnet sodium eye drop release in vitro curve are seen accompanying drawing 2.
Above-mentioned cumulative release curve is discharged equation model, and it has the one-level release rule as a result, and regression equation has good dependency.One-level release fit equation is: Log (Y
∝-Y)=-Kr * t/2.303+M.The release equation of foscarnet sodium gel for eye use of the present invention is: Log (Y
∝-Y)=-0.1814t+1.8524, correlation coefficient is 0.9981.
The result shows that the external drug release rate of foscarnet sodium eye drop is very fast, and the 1.5h release reaches about 80%, enters plateau afterwards; And the foscarnet sodium instant gel for eye reaches about 80% in the 3.5h release, and drug release rate is mild, has slow release characteristic preferably.
Conclusion (of pressure testing): the foscarnet sodium instant gel for eye has slow release characteristic preferably.Improve medicine by the present invention and have feasibility in the bioavailability of eye.
Experiment three: ciprofloxacin lactate instant gel for eye release in vitro degree is investigated
Test objective: investigate the release behaviour in vitro of ciprofloxacin lactate instant gel for eye, and compare with eye drop.
Test material: ciprofloxacin lactate instant gel for eye: get among gellan gum 6g and boric acid, the Borax adding water for injection 800ml, heated and boiled, be cooled to 80 ℃, add ciprofloxacin lactate 3g, be cooled to 60 ℃ while stirring, add ethyl hydroxybenzoate 0.5g, stir evenly, and add the injection water, cross microporous filter membrane (0.22 μ m) to 1000ml, aseptic subpackaged, promptly.
Ciprofloxacin lactate eye drop (the bright red eagle Pharmaceutical in Ningbo limited company produces, and the dose contained with the ciprofloxacin lactate instant gel for eye is identical)
Isotonic phosphate buffer liquid (contains NaH in the 1000ml solution
2PO
41.60g, Na
2HPO
47.58g NaCl 4.32g transfers pH to 7.40)
Test method: take by weighing ciprofloxacin lactate instant gel for eye and each 3g of ciprofloxacin lactate eye drop, place bag filter respectively, (removing bubble in the bag) tightened with nylon wire in bag two, is fixed in the 250ml beaker, and release medium is isotonic phosphate buffer liquid 100ml, the bag upper edge is apart from liquid level 1cm, beaker places on the magnetic stirrer, and stirrer is about 2.5cm, temperature control (34 ± 1) ℃, the 5ml that takes a sample at regular intervals adds simultaneously with the fresh phosphate buffer of volume.
Measure the content (is testing index with the ciprofloxacin) of the ciprofloxacin lactate in each sample of being got respectively with colorimetry.Calculate the diffusion release amount that adds up as follows:
C
i＝f(A
i)，Qn＝100Cn+5∑C
i(Q1＝100C
1 i，n＝1，2，3...)
(C
iBe drug level, A is for recording trap, and Q is the drug accumulation burst size, and i, n are respectively the sampling number of times.)
Result of the test: ciprofloxacin lactate instant gel for eye and ciprofloxacin lactate eye drop release in vitro curve are seen accompanying drawing 3.
Above-mentioned cumulative release curve is discharged equation model, and it has the one-level release rule as a result, and regression equation has good dependency.One-level release fit equation is: Log (Y
∝-Y)=-Kr * t/2.303+M.The release equation of ciprofloxacin lactate gel for eye use of the present invention is: Log (Y
∝-Y)=-0.1814t+1.8524, correlation coefficient is 0.9967.
The result shows that the external drug release rate of ciprofloxacin lactate eye drop is very fast, and the 1h release reaches about 80%, enters plateau afterwards; And the ciprofloxacin lactate instant gel for eye reaches about 80% in the 3h release, and drug release rate is mild, has slow release characteristic preferably.
Conclusion (of pressure testing): the ciprofloxacin lactate instant gel for eye has slow release characteristic preferably.Improve medicine by the present invention and have feasibility in the bioavailability of eye.
Test four: tobramycin instant gel for eye animal pharmacodynamics test is investigated
Test objective: to the pharmacodynamics test research of Bacteritic Keratitis in Rabbits
Test material: tobramycin instant gel for eye: get among gellan gum 5g and boric acid, the Borax adding water for injection 800ml, heated and boiled, be cooled to 80 ℃, add tobramycin 3g, be cooled to 60 ℃ while stirring, add ethyl hydroxybenzoate 0.3g, stir evenly, and add the injection water, cross microporous filter membrane (0.22 μ m) to 1000ml, aseptic subpackaged, promptly.
Gernebcin eye drops (Sichuan Fangxiang Medicine Limited Liability Company produces, and institute's content of dispersion is consistent with the tobramycin instant gel for eye)
Experimental animal and material: new zealand rabbit, the male and female dual-purpose, 2.2～2.8kg, totally 50 (provide the animal quality certification number: SCXK (Shandong) 20030004) by Shandong University's Experimental Animal Center;
Bacillus pyocyaneus (ACTT27853), concentration 1 * 10
6CFUml
-1
Staphylococcus aureus (ACTT25923), concentration 2.5 * 10
9CFUml
-1
Escherichia coli (ACTT25922), concentration 1.8 * 10
9CFUml
-1Get by the clinical separation of clinical laboratory of Hospital Attached to Shandong Chinese Medical Univ. Bacteriology Room.
Test method:
1, bacterial keratitis modelling: decide rabbit with rabbit seat clamping,, treat that its back of losing consciousness contains bacteria culture fluid with 1ml syringe extraction 0.1ml and (contains bacillus pyocyaneus 1 * 10 with 2～3 eye drips of 0.5% tetracaine
6CFU, staphylococcus aureus 2.5 * 10
9CFU or escherichia coli 1.8 * 10
9CFU) in the nearly central part of cornea is annotated people's cornea essential layer, make the white bacterial plaque that causes the about 2～3min of diameter, put into single cage respectively and raise treatment.
2, animal GP TH and medication: 50 of model rabbit are divided into the high, medium and low dosage group of tobramycin instant gel for eye (6 times/d of high dose administration, 1～2 droplet/time; Middle 4 times/d of dosed administration, 1～2 droplet/time; 2 times/d of low dosage administration, 1～2 droplet/time), Gernebcin eye drops group (8 times/d, 1～2 droplet/time) and blank group (giving 8 times/d of water for injection, 1～2 droplet/time).Begin medication with 12h after the modeling, schedule to last 5d, carry out dependent observation work every day.
3, observation index: the keratitis pathological changes is cured degree (perusal) and is begun behind cornea inoculated bacteria 6h, every day observed and recorded ordinary circumstance and empyema, redness, corneal clouding, the performance of ulcer isogonism film inflammation, and give rank scores:
0 minute (normally): no empyema, nothing redness, no cornea muddiness, no ulcer;
1 minute (slightly): cornea, do not have empyema, redness arranged, no cornea muddiness, no ulcer;
2 minutes (moderate): cornea has empyema, redness is arranged, no cornea muddiness, slight ulcer;
3 minutes (severe): cornea empyema redness, corneal clouding, ulcer.
Put to death animal on the 6th day in inoculation treatment back, get 10 corneas dos of side section HE and dye in inflammation such as microscopic examination corneal thickness, ulcer, cell infiltration, fibroblast proliferation performance scoring.10 corneas of opposite side are done 24h antibacterial culturing separation detection, staphylococcus aureus, bacillus pyocyaneus and escherichia coli counting contrast statistics.And with the statistical disposition of following pathogen negative conversion rate detection data.
Result of the test: rabbit with bacillus pyocyaneus, staphylococcus aureus, escherichia coli inoculation back grouping according to putting to death rabbit on the 6th day by scoring of ophthalmology illuminator perusal cornea inflammation and treatment back on the 5th day after the above-mentioned treatment, get the scoring of a side 10 corneas section HE dyeing microscopic examination cornea inflammation, two groups of 20 comprehensive statisticss see Table 1.Computing formula is as follows.
Cure rate (%)=(blank inflammation score value-respectively organize inflammation score value)/blank inflammation score value * 100%
The scorching result of the test table of table 1 tobramycin instant gel for eye treatment rabbit cornea
The result shows that to the curative effect of three kinds of pathogenic bacterium mixed infections of rabbit, the cure rate of three dosage groups of tobramycin instant gel for eye is higher, all is better than Gernebcin eye drops.Prompting tobramycin instant gel for eye is compared with Gernebcin eye drops has better therapeutic effect.
Description of drawings
Accompanying drawing 1: Gatifloxacin instant gel for eye and gatifloxacin eye drop release in vitro curve
Accompanying drawing 2: foscarnet sodium instant gel for eye and foscarnet sodium eye drop release in vitro curve
Accompanying drawing 3: ciprofloxacin lactate instant gel for eye and ciprofloxacin lactate eye drop release in vitro curve
The specific embodiment
Below further specify the present invention by specific embodiment, but following examples only are used to the present invention is described without limits to the present invention.
Embodiment one:
Prescription: Gatifloxacin 15g gellan gum 30g
Method for making: get water for injection 4000ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add boric acid 60g, Borax 3g, ethyl hydroxybenzoate 4g, stir to clarify, be heated to 60 ℃, cross microporous filter membrane (0.8 μ m), stir and add Gatifloxacin down, stir evenly, add the injection water, cross microporous filter membrane (0.22 μ m) to 5000ml, aseptic subpackaged, promptly.
Embodiment two:
Prescription: foscarnet sodium 15g gellan gum 18g
Method for making: get among gellan gum and boric acid, the Borax adding water for injection 2700ml, heated and boiled, be cooled to 80 ℃, add foscarnet sodium, be cooled to 60 ℃ while stirring, add ethyl hydroxybenzoate 1.5g again, and add the injection water to 3000ml, and stir evenly, cross microporous filter membrane (0.22 μ m), aseptic subpackaged, promptly.
Embodiment three:
Prescription: ciprofloxacin lactate 15ml gellan gum 30g
Method for making: get among gellan gum and boric acid, the Borax adding water for injection 4000ml, heated and boiled, be cooled to 80 ℃, add ciprofloxacin lactate, be cooled to 60 ℃ while stirring, add ethyl hydroxybenzoate 2.5g, stir evenly, and add the injection water, cross microporous filter membrane (0.22 μ m) to 5000ml, aseptic subpackaged, promptly.
Embodiment four:
Prescription: tobramycin 6g gellan gum 10g carbomer 2g
Method for making: get among gellan gum and boric acid, the Borax adding water for injection 1600ml, heated and boiled is cooled to 80 ℃, add carbomer, fully dissolving adds tobramycin, is cooled to 60 ℃ while stirring, add ethyl hydroxybenzoate 0.8g, stir evenly, and add the injection water, cross microporous filter membrane (0.22 μ m) to 2000ml, aseptic subpackaged, promptly.
Embodiment five:
Prescription: sodium cromoglicate 40g gellan gum 12g
Method for making: get among gellan gum and boric acid, the Borax adding water for injection 1600ml, heated and boiled, be cooled to 80 ℃, add sodium cromoglicate, be cooled to 60 ℃ while stirring, add methyl hydroxybenzoate 0.5g and propylparaben 0.5g, stir evenly, and add the injection water, cross microporous filter membrane (0.22 μ m) to 2000ml, aseptic subpackaged, promptly.
Embodiment six:
Prescription: dexamethasone sodium phosphate 1g gellan gum 24g
Method for making: get water for injection 3200ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add polyoxyethylene sorbitan monoleate 4g, stir, add triethanolamine and glycerol, add ethyl hydroxybenzoate 2g, stir evenly, add dexamethasone sodium phosphate, add the injection water, cross microporous filter membrane (0.22 μ m) to 4000ml, aseptic subpackaged, promptly.
Embodiment seven:
Prescription: polygynax 10g gellan gum 14g
Method for making: get water for injection 1600ml, add gellan gum, chlorobutanol, put in the boiling water bath, stir to clarify, put coldly, add hyaluronate sodium 0.6g, swollen 12h stirs evenly, and adds boric acid, Borax, stir adding polygynax down, filter, add the injection water to 2000ml, cross microporous filter membrane (0.22 μ m), put cold, aseptic subpackaged, promptly.
Embodiment eight:
Prescription: tropicamide 2.5g gellan gum 4g
Method for making: get water for injection 900ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add triethanolamine and glycerol, add methyl hydroxybenzoate 0.4g and propylparaben 0.4g and polyoxyethylene sorbitan monoleate 1g, stir evenly, stir adding tropicamide down, cross microporous filter membrane, add the injection water to 1000ml, 120 ℃ of autoclavings 20 minutes are put cold, aseptic subpackaged, promptly.
Embodiment nine:
Prescription: acyclovir 5g gellan gum 30g
Method for making: get water for injection 4500ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add boric acid, Borax and propylene glycol, add ethyl hydroxybenzoate 2g and polyoxyethylene sorbitan monoleate 6g, stir evenly, add acyclovir, mixing, cross microporous filter membrane, add the injection water, cross microporous filter membrane (0.22 μ m) to 5000g, aseptic subpackaged, promptly.
Embodiment ten:
Prescription: cortisone acetate 10g gellan gum 10g
Method for making: get water for injection 1600ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add boric acid, Borax, add benzalkonium bromide 1g and hyaluronate sodium 10g, stir evenly, add cortisone acetate, add the injection water to 2000ml, cross microporous filter membrane, put cold, aseptic subpackaged, promptly.
Embodiment 11:
Prescription: ribavirin 5g gellan gum 30g
Method for making: get water for injection 4000ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add boric acid, Borax, add phenoxyethanol 2g, stir evenly, add ribavirin, stir evenly, add the injection water to 4000ml, cross microporous filter membrane, aseptic subpackaged, promptly.
Embodiment 12:
Prescription: acyclovir 2g gellan gum 8g methylcellulose 1.5g
Method for making: get water for injection 1800ml, add gellan gum, methylcellulose, stir, put in the boiling water bath, stir to clarify, add boric acid, Borax, add phenoxyethanol 2g, stir evenly, add acyclovir, stir evenly, add the injection water to 2000ml, cross microporous filter membrane, aseptic subpackaged, promptly.
Embodiment 12:
Prescription: sodium cromoglicate 20g gellan gum 7g
Method for making: get water for injection 900ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add boric acid, Borax, add phenoxyethanol 0.8g, stir evenly, add sodium cromoglicate, stir evenly, add the injection water to 1000ml, cross microporous filter membrane, aseptic subpackaged, promptly.
Embodiment 13:
Prescription: clonidine hydrochloride 5g gellan gum 12g
Method for making: get water for injection 1800ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add polyoxyethylene sorbitan monoleate 1.5g, stir, add triethanolamine and glycerol, add ethyl hydroxybenzoate 1g, stir evenly, add clonidine hydrochloride, add the injection water, cross microporous filter membrane (0.22 μ m) to 2000ml, aseptic subpackaged, promptly.
Embodiment 14:
Prescription: norfloxacin 9g gellan gum 18g
Method for making: get among gellan gum and boric acid, the Borax adding water for injection 2400ml, heated and boiled, be cooled to 80 ℃, add norfloxacin, be cooled to 60 ℃ while stirring, add methyl hydroxybenzoate 0.8g and propylparaben 0.8g, stir evenly, and add the injection water, cross microporous filter membrane (0.22 μ m) to 3000ml, aseptic subpackaged, promptly.
Embodiment 15:
Prescription: foscarnet sodium 15g gellan gum 18g
Method for making: get among gellan gum and boric acid, the Borax adding water for injection 2700ml, heated and boiled, be cooled to 80 ℃, add foscarnet sodium, be cooled to 60 ℃ while stirring, add ethyl hydroxybenzoate 1.5g again, and add the injection water to 3000ml, and stir evenly, cross microporous filter membrane (0.22 μ m), aseptic subpackaged, promptly.
Embodiment 16:
Prescription: chloromycetin 5g gellan gum 10g
Method for making: get water for injection 1800ml, add gellan gum, chlorobutanol, put in the boiling water bath, stir to clarify, put coldly, add boric acid, Borax, stirring makes dissolving, adds HYDROXYPROPYL BETA-CYCLODEXTRIN 3g, mixing, stir and add chloromycetin down, filter, add the injection water, cross microporous filter membrane (0.22 μ m) to 2000ml, aseptic subpackaged, promptly.
Embodiment 17:
Prescription: tobramycin 6g dexamethasone 2g gellan gum 12g
Method for making: get among gellan gum and boric acid, the Borax adding water for injection 1600ml, heated and boiled, be cooled to 80 ℃, add tobramycin and dexamethasone, be cooled to 60 ℃ while stirring, add ethyl hydroxybenzoate 1g, stir evenly, and add the injection water, cross microporous filter membrane (0.22 μ m) to 2000ml, aseptic subpackaged, promptly.
Embodiment 18:
Prescription: taurine 10 g aminocaproic acid 10g Aspartic Acid 1.55g chlorphenamine maleate 0.1g gellan gum 6g
Method for making: get water for injection 900ml, add gellan gum, stir; put in the boiling water bath, stir to clarify, add boric acid, Borax; add benzalkonium bromide 0.6g and hyaluronate sodium 0.8g; stir evenly, add taurine, aminocaproic acid, Aspartic Acid, chlorphenamine maleate, stir and make dissolving; add the injection water to 1000ml; cross microporous filter membrane, aseptic subpackaged, promptly.
Embodiment 19:
Prescription: berberine hydrochloride 3g zinc sulfate 9g gellan gum 18g
Method for making: get water for injection 2700ml, add gellan gum, stir, put in the boiling water bath, stir to clarify, add boric acid 60g, add ethyl hydroxybenzoate 0.9g, stir evenly, add berberine hydrochloride and zinc sulfate, stir and make dissolving, add the injection water to 3000ml, cross microporous filter membrane, aseptic subpackaged, promptly.
Claims (10)
1, a kind of instant gel for eye is to be made by the conventional adjuvant of effective ingredient, gel base material and ophthalmic preparation, and the main component that it is characterized in that the gel base material is a gellan gum.
2, instant gel for eye according to claim 1 is characterized in that containing 0.4～0.7 part of gellan gum in 100 parts of finished weights.
3, instant gel for eye according to claim 2 is characterized in that containing 0.6 part of gellan gum in 100 parts of finished weights.
4; according to claim 1; 2 or 3 described instant gel for eye is characterized in that the effective ingredient of medicine mainly comes from following at least a crude drug: Gatifloxacin; pirenzepine hydrochloride; raceanisodamine; pilocarpine nitrate; isoproterenol; bunazosin; maleic acid Saimaa Luo Er; the husky tropane in a left side; latanoprost; Quwo prostatitis element; bimatoprost; timolol; brimonidine tartrate; betaxolol hydrochloride; carteolol hydrochloride; erythromycin; chloromycetin; ciprofloxacin; ciprofloxacin lactate; ofloxacin; levofloxacin; moxifloxacin hydrochloride; levofloxacin hydrochloride; macrodex; neo-houttuyninum; atropine sulfate; ribavirin; ftibamzone; tiopronin; ciclosporin; ganciclovir; vitamin A palmitate; azithromycin; clarithromycin; raceanisodamine; ketotifen fumarate; netilmicin sulfate; indomethacin; phacolin; Bernetine Sodium; glutathion; vitamin B12; vitamin B6; taurine; bendazac lysine; tranilast; metipranolol; doxycycline hyclate; troxerutin; dexamethasone sodium phosphate; polygynax; fluorometholone; allantoin; chondroitin sulfate; tropicamide; brimonidine; sodium cromoglicate; clonidine hydrochloride; tetracaine hydrochloride; prednisolone acetate; flurbiprofen sodium; ketotifen fumarate; norfloxacin; epalrestat; amosulalol; voriconazole; itraconazole; ammonia iodine peptide; isepamicin; pranoprofen; Bu Linzuo amine; sulphacetamide; chlortetracycline hydrochloride; trifluorothymidine; sodium chromoglicate; the left-handed bunolol of hydrochloric acid; mensiso; the toluenesulfonic acid tosufloxacin; betamethasone sodium phosphate; amlexanox; physostigmine salicylate; sulfadiazine; quadracycline; Naphazoline Chloridum; chlorphenamine maleate; tobramycin; gentamycin sulfate; lincomycin hydrochloride; oxymetazoline hydrochloride; ketorolac tromethamine; natamycin; Micronomicin Sulfate; Ciclosporin A; asparagic acid azithromycin; methylbromtropin; amikacin; fluconazol; ketoconazole; miconazole; econazole; diclofenac sodium; acyclovir; puerarin; zinc sulfate; zinc gluconate; Sodium Houttuyfonate; puerarin; chlorogenic acid; berberine hydrochloride; Borneolum Syntheticum; Mentholum.
5, instant gel for eye according to claim 4 is characterized in that can also containing in the gel base material in carbomer, hydroxypropyl emthylcellulose, poloxamer 407, poloxamer 188, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, methylcellulose, the sodium alginate one or more.
6, instant gel for eye according to claim 4, the hyaluronate sodium that it is characterized in that can also adding the HYDROXYPROPYL BETA-CYCLODEXTRIN of 0～1 part polyoxyethylene sorbitan monoleate or 0～1 part or 0～1 part in 100 parts of finished products improves the state of preparation.
7, instant gel for eye according to claim 6 is characterized in that the conventional adjuvant of used ophthalmic preparation contains isoosmotic adjusting agent, pH regulator agent, antibacterial and water.
8, instant gel for eye according to claim 7, it is characterized in that isoosmotic adjusting agent is at least a in glucose, boric acid, Borax, glycerol, propylene glycol, the mannitol, the pH regulator agent is at least a in hydrochloric acid, citric acid, glacial acetic acid, triethanolamine, boric acid, the Borax, and antibacterial is at least a in benzyl alcohol, chlorobutanol, benzalkonium chloride, benzalkonium bromide, phenoxyethanol, Metagin, second, the propyl ester.
9, instant gel for eye according to claim 8, the addition that it is characterized in that the pH regulator agent to the pH value of preparation is to get final product in 5～8 o'clock, the addition of isoosmotic adjusting agent to the osmotic pressure of preparation for wait ooze or near etc. ooze and get final product, the addition of antibacterial then need reach antibacterial standard.
10, the method for preparing arbitrary described instant gel for eye in the claim 1 to 9, it is characterized in that: will add the gel base material in the water for injection, mixing adds isoosmotic adjusting agent, pH regulator agent, antibacterial etc., mixing again, adding is with the appropriate solvent dissolved drug, filter, add the injection water, filter to total amount, aseptic subpackaged, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810105214XA CN101564374A (en) | 2008-04-25 | 2008-04-25 | Medicinal in situ forming eye gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810105214XA CN101564374A (en) | 2008-04-25 | 2008-04-25 | Medicinal in situ forming eye gel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101564374A true CN101564374A (en) | 2009-10-28 |
Family
ID=41280851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810105214XA Pending CN101564374A (en) | 2008-04-25 | 2008-04-25 | Medicinal in situ forming eye gel |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101564374A (en) |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102727423A (en) * | 2012-06-20 | 2012-10-17 | 贵州大学 | Betaxolol hydrochloride ion-sensitive eye-use in-situ gel and preparation method thereof |
| CN102743760A (en) * | 2011-04-22 | 2012-10-24 | 天津金耀集团有限公司 | Bacteriostatic agent GellanGum-containing externally-used composite for eyes |
| CN102885768A (en) * | 2012-11-02 | 2013-01-23 | 江苏吉贝尔药业有限公司 | Pranoprofen in-situ gelling eye drop and preparation method thereof |
| CN102085203B (en) * | 2009-12-02 | 2013-01-30 | 沈阳兴齐眼药股份有限公司 | Ophthalmic preparation of levofloxacin and prednisolone acetate and preparation method thereof |
| CN102949331A (en) * | 2011-08-19 | 2013-03-06 | 苏州太湖美药业有限公司 | Preparation method of tobramycin ophthalmic in-situ gel eye-drops |
| CN103126981A (en) * | 2013-03-05 | 2013-06-05 | 宁夏康亚药业有限公司 | Foscarnet sodium eye drops and preparation method |
| CN103142462A (en) * | 2012-02-23 | 2013-06-12 | 四川大学 | Brinzolamide eye preparations, and preparation method and use thereof |
| CN103239390A (en) * | 2013-05-15 | 2013-08-14 | 中国人民解放军第三军医大学第二附属医院 | Tropicamide ophthalmic temperature-sensitive in-situ gel and preparation method thereof |
| US20140086975A1 (en) * | 2010-10-15 | 2014-03-27 | Rutgers, The State University Of New Jersey | Hydrogel formulation for dermal and ocular delivery |
| CN103720641A (en) * | 2013-11-25 | 2014-04-16 | 中国中医科学院中药研究所 | Taurine-containing ophthalmic in-vivo gel preparation and preparation method thereof |
| CN103919717A (en) * | 2014-04-15 | 2014-07-16 | 天津中医药大学 | Brimonidine d-tartrate ophthalmic gel preparation as well as preparation method and application thereof |
| CN104039307A (en) * | 2011-04-22 | 2014-09-10 | 爱尔康研究有限公司 | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
| CN104055729A (en) * | 2013-03-22 | 2014-09-24 | 上海现代药物制剂工程研究中心有限公司 | Azithromycin eye drops and preparation method thereof |
| CN104069118A (en) * | 2014-07-01 | 2014-10-01 | 四川兴科蓉药业有限责任公司 | Eye-drop and preparation method thereof |
| CN104721130A (en) * | 2013-02-21 | 2015-06-24 | 四川大学 | Brinzolamide clathrate compound preparation used for eyes and preparation method thereof |
| CN105106107A (en) * | 2015-09-16 | 2015-12-02 | 杭州谷歌医药开发有限公司 | Eye gellan gum in-situ gel made of bendazac lysine and preparing method of eye gellan gum in-situ gel |
| CN105232449A (en) * | 2015-10-30 | 2016-01-13 | 上海昊海生物科技股份有限公司 | Moxifloxacin hydrochloride sodium hyaluronate controlled-release nanogel and preparation method thereof |
| CN106619573A (en) * | 2016-12-27 | 2017-05-10 | 广州中大南沙科技创新产业园有限公司 | Timolol maleate cubic liquid crystal nanoparticle eye drops and preparation method thereof |
| CN107982212A (en) * | 2017-11-28 | 2018-05-04 | 杭州赫尔斯科技有限公司 | A kind of atropic category medicament slow release eye drops and preparation method thereof |
| WO2018126522A1 (en) * | 2017-01-05 | 2018-07-12 | 首都医科大学附属北京朝阳医院 | Injectable intraocular sustained-release antiviral drug and manufacturing method and application thereof |
| CN109010268A (en) * | 2018-09-28 | 2018-12-18 | 湖北远大天天明制药有限公司 | A kind of ophthalmic composition and preparation method thereof improving chloramphenicol stability |
| CN109106684A (en) * | 2018-09-04 | 2019-01-01 | 广州君博医药科技有限公司 | A kind of non-steroidal anti-inflammatory gel for eye use and preparation method thereof |
| CN109200053A (en) * | 2018-11-17 | 2019-01-15 | 王海玲 | A kind of anti-epileptic external drug and application thereof |
| CN109316445A (en) * | 2018-11-15 | 2019-02-12 | 塔里木大学 | A spray for cattle and sheep eye diseases |
| CN109481434A (en) * | 2018-12-18 | 2019-03-19 | 湖北远大天天明制药有限公司 | Eye drops, and the preparation method and application thereof |
| CN109966245A (en) * | 2019-04-03 | 2019-07-05 | 浙江省医学科学院 | A kind of brimonidine tartrate gellan gum type in-situ gel eye drops and preparation method |
| CN110200904A (en) * | 2019-05-27 | 2019-09-06 | 上海昊海生物科技股份有限公司 | A kind of drop intraocular pressure sustained release eye drop composition and preparation method thereof |
| CN111228034A (en) * | 2020-01-16 | 2020-06-05 | 贵州省人民医院 | A drug-loaded controlled-release lacrimal duct embolus and preparation method thereof |
| CN111643448A (en) * | 2020-02-27 | 2020-09-11 | 江苏艾立康药业股份有限公司 | Moxifloxacin hydrochloride ophthalmic gel and preparation method thereof |
| CN112618480A (en) * | 2020-11-10 | 2021-04-09 | 南昌大学 | Preparation method of novel ocular drug delivery system |
| CN113786380A (en) * | 2021-09-18 | 2021-12-14 | 华北制药股份有限公司 | A kind of pilocarpine nitrate ophthalmic gel and preparation method thereof |
| CN115487139A (en) * | 2022-09-13 | 2022-12-20 | 杭州医学院 | A kind of puerarin-gellan gum ionic in-situ gel eye drops and its preparation method |
| CN115998943A (en) * | 2022-12-20 | 2023-04-25 | 北京中医药大学 | Hydrogel for promoting skin wound healing and its application |
| CN116392438A (en) * | 2023-03-30 | 2023-07-07 | 贵州医科大学 | A kind of pranoprofen ion-sensitive ophthalmic in situ gel and preparation method thereof |
| CN116474154A (en) * | 2022-12-20 | 2023-07-25 | 北京中医药大学 | Hydrogel dressing band-aid for diabetic wounds and its application |
| WO2024104313A1 (en) * | 2022-11-18 | 2024-05-23 | Govita Tech Limited | Composition for antiviral or oxidation pretreatment, preparation method and usage method thereof |
-
2008
- 2008-04-25 CN CNA200810105214XA patent/CN101564374A/en active Pending
Cited By (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9763968B2 (en) | 2004-12-22 | 2017-09-19 | Rutgers, The State University Of New Jersey | Hydrogel formulation for dermal and ocular delivery |
| CN102085203B (en) * | 2009-12-02 | 2013-01-30 | 沈阳兴齐眼药股份有限公司 | Ophthalmic preparation of levofloxacin and prednisolone acetate and preparation method thereof |
| US20140086975A1 (en) * | 2010-10-15 | 2014-03-27 | Rutgers, The State University Of New Jersey | Hydrogel formulation for dermal and ocular delivery |
| CN102743760A (en) * | 2011-04-22 | 2012-10-24 | 天津金耀集团有限公司 | Bacteriostatic agent GellanGum-containing externally-used composite for eyes |
| CN104039307A (en) * | 2011-04-22 | 2014-09-10 | 爱尔康研究有限公司 | Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents |
| CN102949331A (en) * | 2011-08-19 | 2013-03-06 | 苏州太湖美药业有限公司 | Preparation method of tobramycin ophthalmic in-situ gel eye-drops |
| CN103142462A (en) * | 2012-02-23 | 2013-06-12 | 四川大学 | Brinzolamide eye preparations, and preparation method and use thereof |
| CN103142462B (en) * | 2012-02-23 | 2016-05-11 | 四川大学 | Brinzolamide eye-drops preparations and its production and use |
| CN102727423A (en) * | 2012-06-20 | 2012-10-17 | 贵州大学 | Betaxolol hydrochloride ion-sensitive eye-use in-situ gel and preparation method thereof |
| CN102885768A (en) * | 2012-11-02 | 2013-01-23 | 江苏吉贝尔药业有限公司 | Pranoprofen in-situ gelling eye drop and preparation method thereof |
| CN104721130A (en) * | 2013-02-21 | 2015-06-24 | 四川大学 | Brinzolamide clathrate compound preparation used for eyes and preparation method thereof |
| CN104721130B (en) * | 2013-02-21 | 2018-02-13 | 四川大学 | A kind of brinzolamide inclusion compound eye-drops preparations and preparation method thereof |
| CN103126981A (en) * | 2013-03-05 | 2013-06-05 | 宁夏康亚药业有限公司 | Foscarnet sodium eye drops and preparation method |
| CN104055729A (en) * | 2013-03-22 | 2014-09-24 | 上海现代药物制剂工程研究中心有限公司 | Azithromycin eye drops and preparation method thereof |
| CN103239390B (en) * | 2013-05-15 | 2014-08-06 | 中国人民解放军第三军医大学第二附属医院 | Tropicamide ophthalmic temperature-sensitive in-situ gel and preparation method thereof |
| CN103239390A (en) * | 2013-05-15 | 2013-08-14 | 中国人民解放军第三军医大学第二附属医院 | Tropicamide ophthalmic temperature-sensitive in-situ gel and preparation method thereof |
| CN103720641A (en) * | 2013-11-25 | 2014-04-16 | 中国中医科学院中药研究所 | Taurine-containing ophthalmic in-vivo gel preparation and preparation method thereof |
| CN103919717A (en) * | 2014-04-15 | 2014-07-16 | 天津中医药大学 | Brimonidine d-tartrate ophthalmic gel preparation as well as preparation method and application thereof |
| CN104069118A (en) * | 2014-07-01 | 2014-10-01 | 四川兴科蓉药业有限责任公司 | Eye-drop and preparation method thereof |
| CN104069118B (en) * | 2014-07-01 | 2016-08-24 | 武汉五景药业有限公司 | Eye drop and preparation method thereof |
| CN105106107A (en) * | 2015-09-16 | 2015-12-02 | 杭州谷歌医药开发有限公司 | Eye gellan gum in-situ gel made of bendazac lysine and preparing method of eye gellan gum in-situ gel |
| CN105232449A (en) * | 2015-10-30 | 2016-01-13 | 上海昊海生物科技股份有限公司 | Moxifloxacin hydrochloride sodium hyaluronate controlled-release nanogel and preparation method thereof |
| CN105232449B (en) * | 2015-10-30 | 2019-04-09 | 上海昊海生物科技股份有限公司 | Moxifloxacin hydrochloride sodium hyaluronate sustained-release nanogel and preparation method thereof |
| CN106619573A (en) * | 2016-12-27 | 2017-05-10 | 广州中大南沙科技创新产业园有限公司 | Timolol maleate cubic liquid crystal nanoparticle eye drops and preparation method thereof |
| WO2018126522A1 (en) * | 2017-01-05 | 2018-07-12 | 首都医科大学附属北京朝阳医院 | Injectable intraocular sustained-release antiviral drug and manufacturing method and application thereof |
| CN107982212A (en) * | 2017-11-28 | 2018-05-04 | 杭州赫尔斯科技有限公司 | A kind of atropic category medicament slow release eye drops and preparation method thereof |
| CN109106684A (en) * | 2018-09-04 | 2019-01-01 | 广州君博医药科技有限公司 | A kind of non-steroidal anti-inflammatory gel for eye use and preparation method thereof |
| CN109010268A (en) * | 2018-09-28 | 2018-12-18 | 湖北远大天天明制药有限公司 | A kind of ophthalmic composition and preparation method thereof improving chloramphenicol stability |
| CN109010268B (en) * | 2018-09-28 | 2020-07-10 | 湖北远大天天明制药有限公司 | Ophthalmic composition for improving stability of chloramphenicol and preparation method thereof |
| CN109316445A (en) * | 2018-11-15 | 2019-02-12 | 塔里木大学 | A spray for cattle and sheep eye diseases |
| CN109200053A (en) * | 2018-11-17 | 2019-01-15 | 王海玲 | A kind of anti-epileptic external drug and application thereof |
| CN109481434A (en) * | 2018-12-18 | 2019-03-19 | 湖北远大天天明制药有限公司 | Eye drops, and the preparation method and application thereof |
| CN109481434B (en) * | 2018-12-18 | 2020-11-10 | 湖北远大天天明制药有限公司 | Eye drops, preparation method and application thereof |
| CN109966245A (en) * | 2019-04-03 | 2019-07-05 | 浙江省医学科学院 | A kind of brimonidine tartrate gellan gum type in-situ gel eye drops and preparation method |
| CN110200904A (en) * | 2019-05-27 | 2019-09-06 | 上海昊海生物科技股份有限公司 | A kind of drop intraocular pressure sustained release eye drop composition and preparation method thereof |
| CN110200904B (en) * | 2019-05-27 | 2021-07-23 | 上海昊海生物科技股份有限公司 | A kind of ocular hypotensive sustained-release eye drop composition and preparation method thereof |
| CN111228034A (en) * | 2020-01-16 | 2020-06-05 | 贵州省人民医院 | A drug-loaded controlled-release lacrimal duct embolus and preparation method thereof |
| CN111643448A (en) * | 2020-02-27 | 2020-09-11 | 江苏艾立康药业股份有限公司 | Moxifloxacin hydrochloride ophthalmic gel and preparation method thereof |
| CN112618480A (en) * | 2020-11-10 | 2021-04-09 | 南昌大学 | Preparation method of novel ocular drug delivery system |
| CN112618480B (en) * | 2020-11-10 | 2022-07-12 | 南昌大学 | A kind of preparation method of ocular drug delivery system |
| CN113786380A (en) * | 2021-09-18 | 2021-12-14 | 华北制药股份有限公司 | A kind of pilocarpine nitrate ophthalmic gel and preparation method thereof |
| CN115487139A (en) * | 2022-09-13 | 2022-12-20 | 杭州医学院 | A kind of puerarin-gellan gum ionic in-situ gel eye drops and its preparation method |
| CN115487139B (en) * | 2022-09-13 | 2023-10-27 | 杭州医学院 | Puerarin gellan gum ionic in-situ gel eye drops and preparation method |
| WO2024104313A1 (en) * | 2022-11-18 | 2024-05-23 | Govita Tech Limited | Composition for antiviral or oxidation pretreatment, preparation method and usage method thereof |
| CN115998943A (en) * | 2022-12-20 | 2023-04-25 | 北京中医药大学 | Hydrogel for promoting skin wound healing and its application |
| CN116474154A (en) * | 2022-12-20 | 2023-07-25 | 北京中医药大学 | Hydrogel dressing band-aid for diabetic wounds and its application |
| CN116474154B (en) * | 2022-12-20 | 2024-05-14 | 北京中医药大学 | Hydrogel dressing band-aid for diabetic wounds and its application |
| CN115998943B (en) * | 2022-12-20 | 2024-05-24 | 北京中医药大学 | Hydrogel for promoting skin wound healing and its application |
| CN116392438A (en) * | 2023-03-30 | 2023-07-07 | 贵州医科大学 | A kind of pranoprofen ion-sensitive ophthalmic in situ gel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101564374A (en) | Medicinal in situ forming eye gel | |
| CN101564375A (en) | Chinese medicinal in situ forming eye gel | |
| CN102283799B (en) | Azithromycin gel eye drops and preparation process thereof | |
| TWI826685B (en) | Dissolvable polymeric eye inserts and method of using same | |
| Alase | Sustained ophthalmic delivery of gatifloxacin from in situ gelling system | |
| Kesavan et al. | Preparation and in vitro antibacterial evaluation of gatifloxacin mucoadhesive gellan system | |
| CN107854424A (en) | A kind of azithromycin ocular in-situ gel and preparation method thereof | |
| CN1872026A (en) | New medicinal preparation for vagina | |
| Nanjwade et al. | Formulation and evaluation of micro hydrogel of Moxifloxacin hydrochloride | |
| CN104055729A (en) | Azithromycin eye drops and preparation method thereof | |
| Bharath et al. | Development and evaluation of a pH triggered in situ ocular gel of brimonidine tartrate | |
| WO2024045973A1 (en) | Use of dehydroepiandrosterone in preparation of medicament for preventing and treating ocular myopia, dosage form thereof, and preparation method therefor | |
| Jothi et al. | In-situ ophthalmic gels for the treatment of eye diseases | |
| CN106265701B (en) | A kind of temperature sensitive hydrogel eye drops and its preparation method and application | |
| CN101579305A (en) | Ready-to-use puerarin ophthalmic gel | |
| CN113786380A (en) | A kind of pilocarpine nitrate ophthalmic gel and preparation method thereof | |
| CN102008488B (en) | Triamcinolone acetonide ophthalmic preparation and preparation method thereof | |
| CN101579357A (en) | Ready-to-use fel ursi ophthalmic gel | |
| CN101579358A (en) | Ready-to-use traditional Chinese medicine ophthalmic gel | |
| CN102008427A (en) | Latanoprost ophthalmic in situ slow release gel | |
| CN101579498A (en) | Ready-to-use zedoary turmeric oil ophthalmic gel | |
| CN101579403A (en) | Ready-to-use Dactylicapnos scandens ophthalmic gel | |
| CN101632717A (en) | In situ forming eye gel preparation for treating myopia and asthenopia and preparation method thereof | |
| Dasankoppa et al. | Design, development and evaluation of cationic guar and hydroxypropylguar based in situ gels for ophthalmic drug delivery | |
| CN101579402A (en) | Ready-to-use decumbent corydalis tuber ophthalmic gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20091028 |